Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CMK389 in Chronic Pulmonary Sarcoidosis
NCT04064242Phase 2Completed
- Sponsor
- Novartis
- Start
- Sep 2020
- Primary completion
- Sep 2023
- Modality
- Monoclonal Antibodies
- Countries
- 6
01
Overview
A Phase 2 trial of CMK-389 in Chronic Pulmonary Sarcoidosis, sponsored by Novartis. Started Sep 2020; status: completed.
02
Drugs
CMK-389
03
Conditions
Chronic Pulmonary Sarcoidosis
Beyond the preview
Go deeper on NCT04064242.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04064242.